AR080433A1 - Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.

Info

Publication number
AR080433A1
AR080433A1 ARP110100621A ARP110100621A AR080433A1 AR 080433 A1 AR080433 A1 AR 080433A1 AR P110100621 A ARP110100621 A AR P110100621A AR P110100621 A ARP110100621 A AR P110100621A AR 080433 A1 AR080433 A1 AR 080433A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
independently selected
hydrogen
substituted
Prior art date
Application number
ARP110100621A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/070831 external-priority patent/WO2011106929A1/en
Priority claimed from PCT/CN2010/080332 external-priority patent/WO2011106986A1/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR080433A1 publication Critical patent/AR080433A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la que cada R1 se selecciona independientemente entre el grupo que consiste en halo, alquilo C1-6, -O-(alquilo C1-6), -O-(haloalquilo C1-6) y -CN; n es 0, 1 , 2 , 3 o 4; R2 es C(O)NRaRb; Ra y Rb se seleccionan independientemente entre el grupo que consiste en hidrogeno, alquilo C1-6 y O(alquilo C1-6); R3 es ArA, donde ArA es un sistema de anillo aromático seleccionado entre el grupo que consiste en: i) anillos monocíclicos de 5 o 6 miembros, y ii) anillos bicíclicos de 8, 9 o 10 miembros, y donde dicho ArA está sustituido por 0, 1, 2, 3 o 4 sustituyentes Rc; cada Rc se selecciona independientemente entre el grupo que consiste en halogeno, OH, alquilo C1-6, O(alquilo C1-6), CN, (CH2)0-3-ArB, donde cada ArB es un sistema de anillo aromático seleccionado independientemente entre el grupo que consiste en: i) anillos monocíclicos de 5 o 6 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, y ii) anillos bicíclicos de 8, 9 o 10 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, (CH2)0-3NRdC(O)Re, (CH2)0-3NRdSO2Re, (CH2)0-3C(O)NRdRe, (CH2)0-3SO2Re, y -OSO2(alquilo C1-6), donde cada Rc alquilo C1-6, O(alquilo C1-6), y (CH2)0-3-ArB está sustituido por 0, 1, 2, 3 o 4 sustituyentes Rf; cada Rd se selecciona independientemente entre el grupo que consiste en hidrogeno y alquilo C1-6; cada Re se selecciona independientemente entre el grupo que consiste en hidrogeno, alquilo C1-6, Oalquilo C1-6 y anillos monocíclicos de 5 o 6 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, donde cada Re alquilo C1-6, Oalquilo C1-6 y anillos monocíclicos de 5 o 6 miembros está sustituido por 0, 1, 2, 3 o 4 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, O(alquilo C1-6), halogeno y OH; cada Rf se selecciona independientemente entre el grupo que consiste en: halogeno, alquilo C1-6, O(alquilo C1-6), CN, N(Rq)2, OH, C(O)H, NHC(O)Rs, NHS(O)2Rs, C(O)NHRq, C(O)ORq, OS(O)2(alquilo C1-6), (CH2)0-3-ArC, donde cada ArC es un sistema de anillo aromático seleccionado independientemente entre el grupo que consiste en: i) anillos monocíclicos de 5 o 6 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, y ii) anillos bicíclicos de 8, 9 o 10 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, donde cada Rf alquilo C1-6, O(alquilo C1-6), y (CH2)0-3-ArC está sustituido por 0, 1, 2, 3 o 4 sustituyentes Rg; cada Rg se selecciona independientemente entre el grupo que consiste en halogeno, N(Rq)2, alquilo C1-6, CN, O(alquilo C1-6), CF3 y C(O)OH; R4 selecciona entre el grupo que consiste en NRhRi; Rh se selecciona entre el grupo que consiste en: hidrogeno, alquilo C1-6, C(O)O(alquilo C1-6), y SO2Rj; Rj se selecciona entre el grupo que consiste en alquilo C1-6, arilo C6-10, cicloalquilo C3-7 y NRxRy, donde Rx y Ry se seleccionan independientemente entre el grupo que consiste en hidrogeno y alquilo C1-6; Ri se selecciona entre el grupo que consiste en: alquilo C1-6, alquenilo C2-6, alquinilo C2-6, (CH2)0-3(cicloalquilo C3-8), (CH2)0-3(cicloalquenilo C3-8), alquilo C(O) C1-6, y heterociclilo, donde Ri está sustituido por 0, 1, 2, 3 o 4 grupos Rk; cada Rk se selecciona independientemente entre el grupo que consiste en: OR1, halogeno, CN, NRmRn, Oalquilo C(O) C1-6, C(O)Oalquilo C1-6, (CH2)0-3-ArD, donde cada ArD es un sistema de anillo aromático seleccionado independientemente entre el grupo que consiste en: i) anillos monocíclicos de 5 o 6 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, y ii) anillos bicíclicos de 8, 9 o 10 miembros con 0, 1, 2, 3 o 4 átomos heteroátomos en el anillo seleccionados independientemente entre el grupo que consiste en N, O o S, donde cada Rk Oalquilo C(O) C1-6, C(O)Oalquilo C1-6, y (CH2)0-3-ArD está sustituido por 0, 1, 2, 3 o 4 grupos Ro; Rl se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 y fenilo; Rm se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6 y (CH2)0-3(fenilo); Rn se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6, SO2(alquilo C1-6), -C(O)H, -C(O)OH, -C(O)O(alquilo C1-6) y C(O)(alquilo C1-6); o Rm y Rn se toman junto con el átomo de N al que están unidos para formar un anillo de 5 a 7 miembros sustituido por 0, 1, 2 o 3 Rp; cada Ro se selecciona independientemente entre el grupo que consiste en halogeno, alquilo C1-6, Oalquilo C1-6 y C(O)O(alquilo C1-6); cada Rp se selecciona independientemente entre el grupo que consiste en halogeno, alquilo C1-6, Oalquilo C1-6, oxo y C(O)O(alquilo C1-6); cada Rq se selecciona independientemente entre el grupo que consiste en H y alquilo C1-6; cada Rs se selecciona independientemente entre el grupo que consiste en alquilo C1-6, heterociclilo y arilo C6-10, donde dicho grupo heterociclilo puede estar opcionalmente sustituido en un nitrogeno o en un átomo de carbono del anillo por un grupo -C(O)O-(alquilo C1-6); y cada Rt se selecciona independientemente entre el grupo que consiste en alquilo C1-6 y arilo C6-10; o Rh y Ri se toman junto con el átomo de N al que están unidos para formar un anillo de 5 a 7 miembros.
ARP110100621A 2010-03-02 2011-03-01 Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. AR080433A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/070831 WO2011106929A1 (en) 2010-03-02 2010-03-02 Inhibitors of hepatitis c virus ns5b polymerase
US32046310P 2010-04-02 2010-04-02
PCT/CN2010/080332 WO2011106986A1 (en) 2010-03-02 2010-12-27 Inhibitors of hepatitis c virus ns5b polymerase

Publications (1)

Publication Number Publication Date
AR080433A1 true AR080433A1 (es) 2012-04-11

Family

ID=44541646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100621A AR080433A1 (es) 2010-03-02 2011-03-01 Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.

Country Status (8)

Country Link
US (1) US20120328569A1 (es)
EP (1) EP2542545A4 (es)
JP (1) JP2013521237A (es)
AR (1) AR080433A1 (es)
AU (1) AU2011223394A1 (es)
CA (1) CA2791426A1 (es)
TW (1) TW201136919A (es)
WO (1) WO2011106992A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20130302282A1 (en) 2010-10-26 2013-11-14 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
CN103906512A (zh) * 2011-09-08 2014-07-02 默沙东公司 四环杂环化合物和其治疗病毒疾病的使用方法
WO2013033899A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2014205592A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
WO2014205594A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2015179392A1 (en) * 2014-05-21 2015-11-26 Bristol-Myers Squibb Company 2-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c
WO2016133948A1 (en) * 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
JP6508324B2 (ja) * 2015-02-19 2019-05-08 Jnc株式会社 ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
PE20181094A1 (es) * 2015-09-28 2018-07-09 Bayer Cropscience Ag Derivados heterociclicos condensados sustituidos por 2-(het)arilo como pesticidas
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MY199220A (en) 2015-11-19 2023-10-20 Incyte Corp Heterocyclic compounds as immunomodulators
JP6911031B2 (ja) 2015-12-22 2021-07-28 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 免疫調節剤としての複素環化合物
WO2017121674A1 (de) * 2016-01-11 2017-07-20 Bayer Cropscience Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
US10280147B2 (en) 2016-03-28 2019-05-07 King Fahd University Of Petroleum And Minerals Solid-supported palladium (II) complex as a heterogeneous catalyst for cross coupling reactions and methods thereof
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197280A (en) 2016-06-20 2023-06-09 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corporation derivados de benzo-oxazol como imunomoduladores
PT3558990T (pt) 2016-12-22 2022-11-21 Incyte Corp Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
PH12022550754A1 (en) 2019-09-30 2023-08-23 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN114805261B (zh) * 2021-01-18 2023-03-21 沈阳药科大学 苯并呋喃类lsd1抑制剂及其制备方法
CN112876518B (zh) * 2021-01-29 2024-08-06 上海弗屈尔光电科技有限公司 一种有机金属配合物和含有该化合物的有机光电元件
EP4176875A1 (en) * 2021-11-04 2023-05-10 Université de Bordeaux Pharmaceutical composition, its use as a drug and new compounds, especially for treating sars-cov-2 infection
AU2022381706A1 (en) * 2021-11-04 2024-05-23 Centre National De La Recherche Scientifique Pharmaceutical composition, its use as a drug and new compounds, especially for treating sars-cov-2 infection
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
US20120328569A1 (en) 2012-12-27
CA2791426A1 (en) 2011-09-09
WO2011106992A8 (en) 2012-02-09
WO2011106992A1 (en) 2011-09-09
EP2542545A1 (en) 2013-01-09
EP2542545A4 (en) 2013-12-25
AU2011223394A1 (en) 2012-09-06
JP2013521237A (ja) 2013-06-10
TW201136919A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
AR080433A1 (es) Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
AR087791A1 (es) Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR083069A1 (es) Analogos de nucleotidos sustituidos
ES2585330T3 (es) Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR088441A1 (es) Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR087793A1 (es) Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR080185A1 (es) Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
PE20251594A1 (es) Derivado policiclico de carbamoilpiridona
AR085602A1 (es) Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes
AR088246A1 (es) Derivados de etinilo
AR057034A1 (es) Metodos para purificar tigeciclina
AR112274A1 (es) Compuestos bicíclicos de cetona y sus métodos de uso
AR087563A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Legal Events

Date Code Title Description
FB Suspension of granting procedure